Resumen
Metastatic colorectal cancer (mCRC) represents a significant burden in cancer-related morbidity and mortality. The study of mCRC-related genetic alterations and the molecular landscape of the disease has been ongoing and continues to improve the efficacy of the available treatment options. Here, we review various molecular pathways that are involved in colorectal carcinogenesis with driving mutations that could be targeted for precision approaches in the treatment of mCRC. We summarize groundbreaking clinical trials that are shaping the evolving role of precision approaches in the practice guidelines and discuss the latest advancements in emerging new modalities, novel technologies, and future directions toward individualizing the managemet approaches to the treatment of colorectal cancer.